



# Pharmacy News

Volume 2: Issue 12

December 2003



## MTF FORMULARY UPDATE

October 2003:

### Additions

#### Sarna (camphor/menthol) (TELEDERM USE ONLY)

- therapeutic category=topical
- clinical applications=anti-itch/mild-weak analgesic  
selectively stimulates the sensory nerve endings for cold & hence causes a sensation of coolness
- adult dose= apply daily as needed for itching

#### Cetaphil Cleanser (TELEDERM USE ONLY)

- therapeutic category=topical
- clinical applications=skin cleanser (soap substitute)
- adult dose= use as needed, as directed for skin cleansing

### Clarifications

Zolmitriptan was added to the BCF effective 11 July 2003. Zolmitriptan is a **DoD Mandatory Source Contract item**. MTFs must have zolmitriptan on their formularies. MTFs are allowed, but not required, to have one additional triptan on their formularies in addition to zolmitriptan. MTFs may not have more than two triptans on formulary. Hence, it was decided at the P&T committee meeting to carry Zomig® (zolmitriptan) and Imitrex® (sumatriptan).

## FDA WARNING

The FDA has a warning letter about excessive use of FD&C#1. The warning letter can be found at their website. It includes the following information:

- Use of Blue 1-tinted enteral feedings for detecting aspiration has been associated with several serious adverse events, including death, although a direct causal relationship has not been definitively established.
- The safety of Blue 1-tinted enteral feedings for detecting aspiration has not been documented.
- Based on reports received to date, patients at risk for increased intestinal permeability (those with sepsis, burns, trauma, shock, surgical interventions, renal failure, celiac sprue, or inflammatory bowel disease, appear to be at an increased risk of absorbing Blue 1 from tinted enteral feedings.

## Drug Product Shortage Bulletin

### CURRENT SHORTAGES:

\*\*For a complete list, please call pharmacy at 569-3034 or check the ASHP website at [www.ashp.org](http://www.ashp.org)

## ADR's

**Adverse drug reactions** include any reaction to a drug that is unexpected or undesirable and results in:

- a change in drug therapy including a change in dosage or discontinuation of therapy;
- initial or prolonged hospitalization;
- intervention (supportive treatment) to prevent permanent impairment or damage;
- a life threatening event;
- permanent disability;
- death;
- reaction to a new drug (drug on the market for 3 years or less)

## Reporting ADRs:

- ✖ **Submit** an electronic **DA 4106**
- ✖ **Via CHCS** by typing **WADR** at any prompt
- ✖ **Call WBAMC** pharmacy at **569-1207**

## Examples of Reportable Reactions

### Case Report

48 y/o started on lisinopril  
74 y/o started on Fosamax®  
78 y/o started on Sinemet®  
35 y/o given codeine  
66 y/o given fentanyl  
14 y/o given ibuprofen

### Reaction

cough  
muscular aches  
rash  
hot flushed skin  
pruritis  
angioedema

